NCT05430009View on ClinicalTrials.gov

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

December 15, 2025

Study Completion Date

June 15, 2026

Conditions
Liver MetastasesNon-small Cell Lung Cancer
Interventions
RADIATION

Liver SBRT

24-45 Gy delivered in 3-5 fractions to 1-4 lesions.

DRUG

Pembrolizumab

200 mg every 3 weeks or 400 mg every 6 weeks

Trial Locations (1)

48109

RECRUITING

Veterans Affairs Ann Arbor Healthcare System, Ann Arbor

All Listed Sponsors
collaborator

LUNGevity Foundation

OTHER

lead

VA Ann Arbor Healthcare System

FED